Cat. No.: HY-B0441

Tobramycin

(Synonyms: Nebramycin Factor 6; Deoxykanamycin B)

16 Cited Publications

Customer Review

Based on 16 publication(s) in Google Scholar

Tobramycin (Nebramycin Factor 6) is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms.Tobramycin can be used to pneumonia research caused by Pseudomonas aeruginosa.

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 32986-56-4
Formula: C₁₈H₃₇N₅O₉
Molecular Weight:467.51

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tobramycin Chemical Structure

CAS No.: 32986-56-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (16)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Tobramycin (Nebramycin Factor 6) is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms^[1].Tobramycin can be used to pneumonia research caused by Pseudomonas aeruginosa^[2]^[3].

IC₅₀ & Target

Aminoglycoside

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Vero	IC₅₀	>200 μg/mL Compound: Tobramycin	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 28291943]

In Vitro

Tobramycin (0-50 ng/mL; 24 hours) combinates with mycobacterium fortuitum enzyme (PodA) can greatly decreases P. aeruginosa cell viability^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Pseudomonas aeruginosa
Concentration:

2,10,50 ng/mL
Incubation Time:

24 h
Result:

Greatly decreased cell viability compared to no protein or inactive mycobacterium fortuitum enzyme (PodA) controls while PodA10 alone did not increase cell death.

In Vivo

Tobramycin (50-400 mg/kg/day, i.p., once every 4h) combinates with Meropenem (HY-13678) produces bacterial cell kill effect at low doses of both drugs in murine pneumonia model. ^[3].
Tobramycin (s.c., single dose) LD₅₀ values in mice and rats are 441 and 969 mg/kg, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Murine Model of Pseudomonas aeruginosa Pneumonia Female, Swiss-Webster mice ^[3]
Dosage:

50, 100, 150, 214, and 400 mg/kg/day
Administration:

Intraperitoneal injection (i.p.) ,once every 4h
Result:

Had near-maximal killing of the wild-type bacteria occurred at approximately 150 mg/kg/day when tobramycin alone.
Combinated with Meropenem (HY-13678) produced near-maximal effect (i.e., bacterial cell kill) at low doses of both drugs (60 and 50 mg/kg/day for Meropenem (HY-13678) and tobramycin, respectively).

Animal Model:

Mice, rats, cats and dogs for toxicologic evaluation^[4]
Dosage:

7.5,15,30,120,441,969 mg/kg
Administration:

Subcutaneous injection (s.c.), Intravenous injection (i.v.) ,Intramuscular injection(i.m.)
Result:

The s.c. LD₅₀ values in mice and rats were 441 and 969 mg/kg, respectively.
Within 1 hour after treated, death with central nervous system depression as a precursor occurred in rats and mice.
A 100 mg/kg iv dose in chloraloseanesthetized catsproduced a moderate, transient decreasein blood pressure and a significant decrease in inspiratory volume and soleus twitch force.
Changed renal tissue in rats which were given daily sc doses of 15-120 mg/kg for 3 months.
im dose of 7.5 mg/kg for a l-month had no apparent effect on dogs, but a 30 mg/kg dose for a l-month produced severerenal damage.

Chemical Information

CAS No. 32986-56-4
Appearance Solid
Molecular Weight 467.51
Formula C₁₈H₃₇N₅O₉
Color White to off-white
SMILES

O[C@@H]([C@@H]1O[C@@]([C@@H](C[C@@H]2O)N)([H])O[C@@H]2CN)[C@H]([C@@H](C[C@@H]1N)N)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO
Synonyms

Nebramycin Factor 6; Deoxykanamycin B
Structure Classification
- Antibiotics
- Other Antibiotics
Initial Source
- Microorganisms
Streptomyces tenebrarius
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (16)

All Microbiological AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
MedComm (2020)

Novel antibiotics against Staphylococcus aureus without detectable resistance by targeting proton motive force and FtsH. [Abstract]

2025 Jan 8;6(1):e70046. PMID: 39781293

Tobramycin purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2025 Jan 8;6(1):e70046. [Abstract]

Time-killing curves of drug combinations between STK848198 (0.5 µg/mL) and antibiotics with FICI≤ 0.5 [SM (8 µg/mL)/ Tobramycin (32 µg/mL)/ AMP (2 µg/mL)/ fosfomycin (0.5 µg/mL)/ SIS (32 µg/mL)/ gentamycin (8 µg/mL)].
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
Food Chem

Electrochemical sensor for detecting streptomycin in milk based on label-free aptamer chain and magnetic adsorption. [Abstract]

2023 Mar 1:403:134399. PMID: 36182859
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Int J Mol Sci

Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. [Abstract]

2025 Feb 6;26(3):1381. PMID: 39941149
Appl Microbiol Biotechnol

Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA. [Abstract]

2022 Apr;106(7):2689-2702. PMID: 35338386
ACS Infect Dis

Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]

2024 Apr 12;10(4):1327-1338. PMID: 38567846

Tobramycin purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]

Synergistic antimicrobial efficacy between LP and Tobramycin (TOB) in a murine peritonitis model. The peritonitis mice (n = 6 mice/group) were applied with 5% Kolliphor + 5% ethanol (vehicle), 30 mg/kg VAN, 30 mg/kg LP, and 30 mg/kg TOB alone or in combination twice daily for 1 day. Representative viable cell colony count was collected from the kidney and spleen.

Tobramycin purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]

Synergistic antimicrobial efficacy between LP and Tobramycin (TOB) in a murine peritonitis model. The peritonitis mice (n = 6 mice/group) were applied with 5% Kolliphor + 5% ethanol (vehicle), 30 mg/kg VAN, 30 mg/kg LP, and 30 mg/kg TOB alone or in combination twice daily for 1 day. The viable bacterial counts in the spleen were quantified.

Tobramycin purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]

Synergistic antimicrobial efficacy between LP and Tobramycin (TOB) in a murine peritonitis model. The peritonitis mice (n = 6 mice/group) were applied with 5% Kolliphor + 5% ethanol (vehicle), 30 mg/kg VAN, 30 mg/kg LP, and 30 mg/kg TOB alone or in combination twice daily for 1 day. The viable bacterial counts in kidneys were quantified.

Tobramycin purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]

Synergistic antimicrobial efficacy between LP and Tobramycin (TOB) in a murine peritonitis model. The peritonitis mice (n = 6 mice/group) were applied with 5% Kolliphor + 5% ethanol (vehicle), 30 mg/kg VAN, 30 mg/kg LP, and 30 mg/kg TOB alone or in combination twice daily for 1 day. Quantification of the inflammatory cytokine IL-6 in the serum.
AMB Express

Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]

2024 Dec 24;14(1):141. PMID: 39718732

Tobramycin purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]

Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. Compound combinational activity between PVB and aminoglycosides, respectively. AMK, amikacin. GEN, gentamycin, KANA, kanamycin. TOB, Tobramycin (MIC_alone = 64 μg/mL; MIC_combined = 256 μg/mL). SPC, spectinomycin.
Curr Microbiol

Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. [Abstract]

2021 Dec 14;79(1):12. PMID: 34905092
Theriogenology

Dual roles of the TLR2/TLR4/NLRP3-H-PGDS-PGD2 axis in regulating the inflammatory response in Escherichia coli-infected bovine bone marrow-derived macrophages and endometrial tissue. [Abstract]

2025 Jun:239:117374. PMID: 40112766
Basic Clin Androl

Pelvic vasectomy and its protective effects on rat testis function. [Abstract]

2025 Mar 7;35(1):9. PMID: 40055615
J Microbiol Methods

Comparison of agar-based and checkerboard methods to assess phage-antimicrobial synergy in Pseudomonas aeruginosa. [Abstract]

2026 Feb 25:107441. PMID: 41759663
bioRxiv

2024 May 10.
bioRxiv

2024 Feb 9.

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (213.90 mM)

DMSO : 2 mg/mL (4.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1390 mL

10.6950 mL

21.3899 mL

5 mM

0.4278 mL

2.1390 mL

4.2780 mL

10 mM

0.2139 mL

1.0695 mL

2.1390 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (213.90 mM); Clear solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tobramycin. [Content Brief]

[2]. VanDrisse CM, et.al. Computationally designed pyocyanin demethylase acts synergistically with tobramycin to kill recalcitrant Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022012118. [Content Brief]

[3]. Louie A, et.al. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 2013 Jun;57(6):2788-92. [Content Brief]

[4]. Welles JS, et.al. Preclinical toxicology studies with tobramycin. Toxicol Appl Pharmacol. 1973 Jul;25(3):398-409. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	2.1390 mL	10.6950 mL	21.3899 mL	53.4748 mL
H₂O	5 mM	0.4278 mL	2.1390 mL	4.2780 mL	10.6950 mL
	10 mM	0.2139 mL	1.0695 mL	2.1390 mL	5.3475 mL
	15 mM	0.1426 mL	0.7130 mL	1.4260 mL	3.5650 mL
	20 mM	0.1069 mL	0.5347 mL	1.0695 mL	2.6737 mL
	25 mM	0.0856 mL	0.4278 mL	0.8556 mL	2.1390 mL
	30 mM	0.0713 mL	0.3565 mL	0.7130 mL	1.7825 mL
	40 mM	0.0535 mL	0.2674 mL	0.5347 mL	1.3369 mL
	50 mM	0.0428 mL	0.2139 mL	0.4278 mL	1.0695 mL
	60 mM	0.0356 mL	0.1782 mL	0.3565 mL	0.8912 mL
	80 mM	0.0267 mL	0.1337 mL	0.2674 mL	0.6684 mL
	100 mM	0.0214 mL	0.1069 mL	0.2139 mL	0.5347 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Tobramycin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Glycoside Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Microbial Metabolite Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Bacteria-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Tobramycin

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (16)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tobramycin Related Classifications

Cat. No.: HY-B0441